Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: ASCO Controversies

Executive Summary

Despite the early sell-off in life science stocks during last week’s American Society for Clinical Oncology (ASCO) conference, there were some very positive new developments for cancer patients. The only problem now is the question of who will pay for combination treatment regimens.

You may also be interested in...



Alexion Optimistic Of Soliris' gMG Chances Despite Missing Ph III Target

Alexion Pharmaceuticals Inc. is reassessing its regulatory strategy after Phase III data for its warhorse Soliris in myasthenia gravis, a rare neuromuscular disease, missed statistical significance on the primary endpoint but the company hopes regulators will give the therapy the benefit of the doubt after more data are generated.

Biogen Anti-LINGO MS Study Failure Removes Upside

Biogen’s potential game-changing multiple sclerosis drug anti-LINGO-1 failed to meet the primary or secondary endpoints of a Phase II study, highlighting the challenges the biotech faces developing treatments for serious CNS disorders.

Was Rova-T Worth The High Price To AbbVie?

The big pharma presented early-stage data for its antibody drug conjugate at the American Society of Clinical Oncology (ASCO) in Chicago that showed promise for the drug in a small subset of patients with small cell lung cancer, but had disappointing results for the overall population.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel